Neuland Laboratories announces commercial production of peptides

Written by Businesswire India | Hyderabad | Updated: Aug 27 2009, 22:20pm hrs
Neuland Laboratories Limited, a reliable global provider of APIs and other essential drug discovery and development support services announced successfully commencement of manufacturing of peptides blocks by successfully commercializing the production of Fmoc Pseudoproline Dipeptides and other building blocks in India and the US subsidiary.

In the initial phase the company will target the US and Europe markets. Developing markets will follow in the next phase. Neulands quality of products is superior with attractive pricing and it is poised to penetrate into this peptide synthesis market.

Dr. D R Rao, Chairman & Managing Director, Neuland Laboratories said, We are committed to making Neuland Laboratories the premier peptide service facility in the world, and becoming the preferred choice for the world peptide community. Our foray into peptides is a reflection of our focused plans of being profitable and giving more value to our investors, besides growing our client base.

He added, Over the next two years Neuland will integrate the peptide value chain by leveraging on the existing expertise in API and contract manufacturing, thus creating a niche opportunity for itself in this segment. The company will develop in-house process capabilities for commercial manufacture of peptides

Neuland also announced its foray and focus into High potent APIs (HAPIs) thus making another stride towards bringing more value and synergy to the companys contract research and generic APIs business. The move into this niche market segment reinforces Neulands intent to focus on opportunities that require higher barriers to entry, while also leveraging the companys existing intellectual capital and regulatory strength.

The company has commissioned a new facility for manufacturing of High Potent APIs (HAPIs). The company has also reinforced its R&D resources to support its focus on development of HAPIs.

Neuland has identified and initiated the work in the high growth areas of Vitamin-D analogs, Oncology Nucleosides and Peptides among the other HAPIs where it can capitalize its strengths in chemistry, contract research and manufacturing expertise while projecting the companys business philosophy of quality and on time delivery.

Mr. Sucheth Rao Davuluri, Chief Executive Officer (CEO), Neuland Laboratories Limited said Advances in drug delivery technologies are opening up avenues in High potent APIs (HAPIs), peptides and other niche market segments like Vitamin D analogs. Neuland sees this as a potential area for high growth, which is a synergy with both our contract research and API business. Neuland has also commissioned a new facility for the cGMP manufacturing of High Potent APIs (HAPIs) and also adding the R&D resources to support development of HAPIs.

Neuland will continue to increase its product range by adding approximately 20 new products this year to its existing portfolio of APIs that will help sustain and grow the core capabilities of the company.